Turkish Journal of
Endocrinology and Metabolism
Original Article

Evaluation of DNA Damage in Patients with a Neuroendocrine Tumor

1.

Neuroendocrine Tumor Study Group, Erciyes University Department of Medical Biogology, Erciyes University Faculty of Medicine, Kayseri, Turkey

2.

Department of Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, Turkey

3.

Department of Nuclear Medicine, Erciyes University Faculty of Medicine, Kayseri, Turkey

4.

Deparment of Pathology, Erciyes University Faculty of Medicine, Kayseri, Turkey

5.

Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey

6.

Department of Surgery, Erciyes University Faculty of Medicine, Kayseri, Turkey

7.

Department of Gastroenterology, Erciyes University Faculty of Medicine, Kayseri, Turkey

Turk J Endocrinol Metab 2019; 23: 105-111
DOI: 10.25179/tjem.2019-65610
Read: 230 Downloads: 78 Published: 01 June 2019

ABSTRACT

Objective: Neuroendocrine tumors develop from the neuroendocrine cells of the endocrine system. As these tumors are extremely slow growing compared with other cancers, they often take years to reach a measurable dimension, thus leading to the late diagnosis, which has adverse effects on the survival and quality of life of patients. There is a link between many types of cancer and genomic instability, thus the markers associated with genomic instability can be used for early diagnosis of the disease or cancer-related changes. Comet assay is the most commonly used method to test genomic instability or DNA damage. To the best of our knowledge, no data are available on DNA damage in patients with neuroendocrine tumors. This study aimed to investigate the possible risk of DNA damage in a patient with neuroendocrine tumors using the comet assay.

Material and Methods: The study included 23 patients with neuroendocrine tumors and 20 age-and sex-matched healthy participants. The DNA damage was determined using the comet assay for leukocytes obtained from the peripheral blood samples of patients and control participants.

Results: We found that the DNA damage was markedly higher in the patients with neuroendocrine tumors than control participants (p˂0.05).

Conclusion: Our data suggest that genomic instability contributes to the development of neuroendocrine tumors. However, further investigations are needed to support our results, as it is a preliminary report on DNA damage risk in patients with NETs.

 

 

Files
TURKISH
ISSN 1301-2193 EISSN 1308-9846